LON:N4P - N4 Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 8.15
▲ +0.25 (3.16%)
1 month | 3 months | 12 months
Get New N4 Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for N4P and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for N4P

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for N4 Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 8.15.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in N4 Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/5/2018Beaufort SecuritiesReiterated RatingSpeculative Buy
i
12/22/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12
i
11/30/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12
i
11/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12
i
10/11/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12
i
9/26/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 12
i
7/27/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
7/3/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
(Data available from 4/14/2016 forward)
N4 Pharma logo
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system; and Nanomerics Limited to produce and test two candidate formulations using the Nuvec delivery system. N4 Pharma Plc is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 8.15
7.70
8.20

50 Day Range

MA: GBX 8.62
7.94
9.75

52 Week Range

Now: GBX 8.15
3.80
16

Volume

997,119 shs

Average Volume

2,735,241 shs

Market Capitalization

£14.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of N4 Pharma?

The following sell-side analysts have issued stock ratings on N4 Pharma in the last year:
View the latest analyst ratings for N4P.

What is the current price target for N4 Pharma?

0 Wall Street analysts have set twelve-month price targets for N4 Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for N4 Pharma in the next year.
View the latest price targets for N4P.

What is the current consensus analyst rating for N4 Pharma?

N4 Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for N4P.

What other companies compete with N4 Pharma?

How do I contact N4 Pharma's investor relations team?

N4 Pharma's physical mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company's listed phone number is +44-1332-690061. The official website for N4 Pharma is www.n4pharma.com.